OpenAI bought Orchestra Bio, whose AI agents track drug programs.

Until now, Rosalind covered the science: GPT-Rosalind reasons through biology and chemistry, while Rosalind Workbench links models to lab tools and data.

Orchestra targets a different bottleneck, the coordination work that spreads a drug program across departments, contractors and disconnected software.

Its agents monitor studies and timelines, so when a manufacturing batch fails, they map which trials slip and compare responses for program leaders to choose.

Anthropic paid roughly $400M in stock for Coefficient Bio in April, so both labs are now buying specialist biology teams.

Development still averages 10 to 15 years from target to US approval, a clock largely set by trial biology and regulators.